ICD code M72.4 – Pseudosarcomatous fibromatosis

Key takeaways

ICD-10 code M72.4 describes pseudosarcomatous fibromatosis, a benign soft tissue lesion that mimics sarcoma on imaging.

Nodular fasciitis is an accepted synonym under M72.4, so documentation using that term maps correctly to this code.

M72.4 is a billable, HIPAA-valid code effective FY2026 (October 1, 2025), covered by Medicare and Medicaid.

Practice management software like Pabau pairs with Claim.MD to validate ICD-10 submissions against thousands of US payers.

ICD-10 code M72.4: Definition and billable status

ICD-10 code M72.4 is a valid, specific, billable diagnosis code in the ICD-10-CM classification system. It represents pseudosarcomatous fibromatosis and is accepted on all HIPAA-covered claim transactions. The CDC/NCHS ICD-10-CM web tool confirms M72.4 as effective from October 1, 2025 for fiscal year 2026.

What is pseudosarcomatous fibromatosis?

Pseudosarcomatous fibromatosis is a benign, rapidly growing fibroblastic proliferation of soft tissue that can mimic a malignant sarcoma on both clinical examination and imaging. Despite the alarming name, the lesion is non-cancerous. It arises most often in subcutaneous or intramuscular connective tissue, and it grows quickly. That speed is why the lesion is usually biopsied to rule out malignancy before a code is assigned.

Clinically, the condition affects adults of any age and has no strong sex predilection. Lesions typically appear on the trunk, the upper extremity, or the head and neck region.

The physician’s note must document histological confirmation to support M72.4 over a neoplasm code. Where surgery has not happened yet, strong clinical suspicion from imaging and presentation can stand in. Coders should not assign M72.4 from radiology alone when the pathology report contradicts a fibromatosis classification.

Local recurrence after excision also has coding implications. A recurrence is not a new diagnosis and does not take a different code. The note should still state “recurrent pseudosarcomatous fibromatosis” so auditors can tell it apart from a first presentation.

Approximate synonyms, including nodular fasciitis

Several clinical terms map to ICD-10 code M72.4. Coders need to recognize all of them, because physician documentation varies widely. A missed synonym is the fastest route to an unbillable claim.

• Nodular fasciitis (most common alternative term, listed as an included synonym by AAPC and confirmed in the ICD-10-CM index)
• Proliferative fasciitis
• Pseudosarcomatous fasciitis
• Reactive fibroblastic proliferation

Of these, nodular fasciitis causes the most confusion. It is a widely used clinical term, and some coders search “nodular fasciitis ICD-10” without realizing it maps straight to M72.4.

When the pathology report reads “nodular fasciitis,” M72.4 is the correct code, not a neoplasm code from the D49 range. Verify any alternate descriptor against the AAPC Codify ICD-10-CM lookup before you submit.

Where M72.4 sits in the ICD-10-CM hierarchy

Knowing where M72.4 sits in the classification helps coders navigate the chapter structure and pick the most specific code for each encounter. The hierarchy runs from chapter level down to M72.4:

M72.4 is a terminal, billable code with no further subcategory. The WHO ICD-10 browser confirms the international classification structure, while the CMS tabular list governs the US-specific rules that apply at M72.4. Coders working across the M70-M79 block can browse the neighboring categories in our ICD-10-CM code library.

Related codes in the M72 fibroblastic disorders category

M72.4 shares its parent category with several other fibroblastic disorder codes. Selecting the wrong sibling code is a common denial trigger. The table below shows every M72 subcode alongside its descriptor and the key differentiator from M72.4.

The most consequential distinction for practices billing surgical procedures is M72.4 against M72.2. Plantar fascial fibromatosis (M72.2) is a far more common presentation. Coders sometimes default to it when the note describes a foot or lower extremity lesion. If the pathology is pseudosarcomatous, M72.4 applies regardless of anatomical site.

CPT codes commonly billed with M72.4

M72.4 pairs with procedure codes for excision, biopsy, and imaging when the practice bills for pseudosarcomatous fibromatosis management. The table below lists CPT codes commonly submitted alongside M72.4. These are typical pairings based on clinical workflow, not guaranteed reimbursement combinations. Verify coverage with each payer’s local coverage determination (LCD) before submitting.

Cross-referencing ICD-10 and CPT codes in one system removes the manual step of confirming a pairing before submission. A superbill that pre-populates M72.4 alongside the excision code also removes a common transcription error at the billing desk.

Medicare and payer coverage

M72.4 is covered by Medicare and Medicaid, per the AAPC code page. Coverage does not mean automatic reimbursement. Payers apply medical necessity criteria tied to local coverage determinations (LCDs).

For a benign soft tissue lesion like pseudosarcomatous fibromatosis, prior authorization for surgical excision is common. The documentation must show why watchful waiting was not the right management before an excision claim will clear.

• Medicare: Covered diagnosis. Excision claims should include the operative report and the pathology report. A pre-operative biopsy code billed on a separate date strengthens medical necessity documentation.
• Medicaid: Covered in most state plans. Confirm prior authorization requirements with the specific state Medicaid program, as these vary significantly for soft tissue tumor excision.
• Commercial payers: Coverage varies. Obtain pre-authorization before scheduling excision. Include imaging reports and the clinical note documenting rapid growth or functional impairment as justification.
• HIPAA validity: M72.4 is valid for all HIPAA-covered electronic and paper claim transactions without modification.

Building the pre-authorization step into the workflow before the procedure date, rather than after it, is what keeps M72.4 claims moving. Submitting an excision claim without prior authorization for a non-urgent benign lesion is a predictable denial pattern. Payer rules govern here, not the billable status of the diagnosis code.

Practices submitting M72.4 claims through Pabau can route them via the Claim.MD clearinghouse integration. It validates codes against thousands of US payers and runs real-time eligibility checks.

Remittance files come back in the ERA 835 format, so the payment loop closes without manual reconciliation. The integration handles CMS-1500 and 837P formats, and it flags payer-specific rejections before adjudication.

Coding guidelines and documentation requirements

The physician note decides whether an M72.4 claim survives review. This section covers what the note must contain, the errors that most reliably trigger denials, and the situations where M72.4 does not apply.

What the clinical note must support

• Histological or strong clinical basis: The note must document a pathology report confirming fibromatosis. Where surgery has not happened yet, the clinical rationale carries it. That means rapid growth, imaging consistent with fibromatosis, or prior history.
• Site documentation: The anatomical location should be clearly stated. M72.4 has no site-specific subcodes, but auditors and payers expect the note to describe where the lesion is. That confirms it is not better coded under M72.0 (palmar) or M72.2 (plantar).
• Benign characterization: If the lesion was initially suspected to be malignant, the note must include the final determination. A code from the neoplasm chapter cannot co-exist with M72.4 on the same claim for the same lesion.

Common coding errors to avoid

• Coding from radiology only: Imaging can suggest fibromatosis, but MRI findings alone do not confirm the diagnosis. Use a neoplasm of uncertain behavior code (D49.2) until pathology confirms M72.4, unless the clinical picture is unambiguous.
• Selecting M72.9 (unspecified) when M72.4 applies: When the pathology report says pseudosarcomatous fibromatosis or nodular fasciitis, M72.4 is the specific code. M72.9 should not appear on a claim where the diagnosis is documented.
• Confusing M72.4 with necrotizing fasciitis (M72.6): Pseudosarcomatous fibromatosis is benign. Necrotizing fasciitis is an aggressive infectious process. The terms sound similar, but the codes, the clinical management, and the payer scrutiny differ completely.

Denial management patterns for soft tissue codes show that the most recoverable denials in this category come from a missing pathology report. Attach it at first submission rather than during an appeal. A quarterly audit of M72-category claims will surface weak documentation before a payer does.

When not to use M72.4

• When the pathology report returns a malignant diagnosis: use the appropriate sarcoma code from C49 (malignant neoplasm of connective and soft tissue).
• When the condition is documented as Dupuytren contracture or palmar fascial fibromatosis: use M72.0.
• When the lesion is on the plantar surface and documented as Ledderhose disease: use M72.2.
• When the documentation cannot confirm fibromatosis: use M72.9 and query the physician before the claim is finalized.

Coders meet these rules in reverse, starting from a note rather than a code list. The routing below maps each documented finding onto the code it supports.

Specificity is what protects the money here. An M72.9 on a claim that the pathology report could have supported at M72.4 invites review, and the excision is the expensive line. At the point of billing, claims software for practices catches that mismatch before the claim leaves the building.

How Pabau keeps M72.4 claims clean

A coding mismatch usually surfaces after the remittance comes back. The denial arrives weeks later. Someone has to dig the pathology report out again, and the appeal costs more staff time than the original claim did.

Practice management software like Pabau moves that check to the front of the process. Diagnosis and procedure codes sit on the same patient record as the treatment note. The M72.4 pairing is assembled where the clinical detail already lives, and payer-specific rules can flag an M72-category claim that carries no pathology attachment.

From there the claim goes out through the Claim.MD clearinghouse integration, which checks eligibility and validates the code set before submission. Rejections surface ahead of the payer’s adjudication cycle rather than after it. Your team fixes the M72.4 line once, not twice.

Catch M72.4 errors before the claim goes out

Pabau pairs with Claim.MD to validate ICD-10 codes, run eligibility checks, and route claims to thousands of US payers. Build the documentation workflow that prevents denials instead of appealing them.

Book a demo

Conclusion

Pseudosarcomatous fibromatosis is a benign lesion with a name that reads like a cancer diagnosis. That tension is what makes M72.4 easy to get wrong. The code itself is straightforward once the pathology report is in hand.

So the work sits upstream of the coder. Ask the ordering physician for site and histology in the note itself. Attach the pathology report at first submission, and the specificity argument never has to be made twice.

That habit is worth more than any single code correction. Book a demo to see how Pabau pairs M72.4 with the right procedure code and gets the claim out clean.

Continue your research

Need a structured framework for ICD-10 claim denials? Denial codes in medical billing covers the most common CARC denial reasons and how to appeal them systematically.

Want to understand how clearinghouse validation works? Medical claims clearinghouse guide explains how 837P files are scrubbed, validated, and transmitted to payers.

Exploring how to reduce coding errors across your practice? Superbill best practices outlines how structured superbill templates reduce mismatched diagnosis and procedure code pairings at source.

Frequently asked questions